Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hard to Treat Diseases's Enterprise Value is $0.00 Mil.
Hard to Treat Diseases does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Hard to Treat Diseases's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Hard to Treat Diseases's Enterprise Value is $0.00 Mil.
Hard to Treat Diseases does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Hard to Treat Diseases's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Hard to Treat Diseases's Enterprise Value is $0.00 Mil.
Hard to Treat Diseases does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Hard to Treat Diseases's EV-to-Revenue at this moment.
Hard to Treat Diseases Enterprise Value Historical Data
The historical data trend for Hard to Treat Diseases's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Hard to Treat Diseases Enterprise Value Chart
Hard to Treat Diseases Annual Data
Trend
Enterprise Value
Hard to Treat Diseases Quarterly Data
Enterprise Value
Competitive Comparison of Hard to Treat Diseases's Enterprise Value
For the Biotechnology subindustry, Hard to Treat Diseases's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hard to Treat Diseases's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hard to Treat Diseases's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hard to Treat Diseases's Enterprise Value falls into.
Hard to Treat Diseases Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Hard to Treat Diseases's Enterprise Value for the fiscal year that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hard to Treat Diseases (OTCPK:HTDS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Hard to Treat Diseases Enterprise Value Related Terms
Thank you for viewing the detailed overview of Hard to Treat Diseases's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Hard to Treat Diseases (Hard to Treat Diseases) Business Description
Hard to Treat Diseases Inc operates medical and cosmetics company in Europe, and Mainland China. It is s also in the process of developing its own stem cell bank.
Hard to Treat Diseases (Hard to Treat Diseases) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HTDS has been successfully added to your